TapImmune Shares Higher

TapImmune shares were higher 9% on Tuesday after the company said that in coordination with the U.S. Food and Drug Administration, it has amended the patient inclusion criteria for its phase 2 clinical trial of T-cell therapeutic peptide vaccine TPIV200 to focus on women with stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy.

The company said it has enrolled the first women under this amended study protocol, which expands the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence. The study size was increased to 120 patients to better evaluate the effect of the immunotherapy and to achieve statistical significance of efficacy data. TPIV200 has fast track designation from the FDA and orphan drug status for ovarian cancer.

Leave a Comment